Manjia Xu on Muck Rack

Manjia Xu

As seen in: ONCOLOGY journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Manjia

Contact Manjia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FDA Grants Fast Track Designation to FG001 for High-Grade Glioma Surgery

|
By Ben Brewer, Zebing Luo, Manjia Xu
| ONCOLOGY journal Verified
The FDA has granted fast track designation to FG001, a fluorescent imaging agent targeting the urokinase-type plasminogen activator receptor (uPAR), for use as an intraoperative imaging agent guide during the surgical resection of high-grade glioma (HGG), according to a news release from the developer, FluoGuide.1 The granting of fast track status follows the FDA’s clearance of an investigational new drug (IND) application in February 2026, which paved the way for the initiation of a US-based...
Open in Who Shared Issue with article?

Talazoparib Combo Improves Radiographic PFS in Metastatic HSPC

|
By Ben Brewer, Zebing Luo, Manjia Xu
| ONCOLOGY journal Verified
The combination of talazoparib (Talzenna) plus enzalutamide (Xtandi) exhibited a significant improvement in radiographic progression-free survival (PFS) compared with placebo and enzalutamide as a treatment for patients with HRR-mutated metastatic hormone sensitive prostate cancer (HSPC), according to a news release from the developer, Pfizer.1 Specifically, the results from the phase 3 TALAPRO-3 study (NCT04821622), which compared the efficacy and safety of enzalutamide with talazoparib or...
Open in Who Shared View Duplicates (2) Issue with article?

Highlighting En-Bloc Resection in Bladder Cancer Surgery

|
By Ben Brewer, Zebing Luo, Manjia Xu
| ONCOLOGY journal Verified
The development of en-bloc resection of bladder tumors (ERBT), wherein the tumor is removed in one piece to reduce the risk of tumor reimplantation, has been associated with a significant reduction in 1-year recurrence rates among patients with non–muscle-invasive bladder cancer (NMIBC), according to Jeremy Teoh, MBBS, FRCSEd, FCSHK, FHKAM.
Open in Who Shared Issue with article?
See all 8 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified